LncRNA CASC2 is up-regulated in osteoarthritis and participates in the regulation of IL-17 expression and chondrocyte proliferation and apoptosis

Tao Huang,Donghua Hang,Jian Wang,Yuan Zhou,Yun Cao,Yi Zhao

doi:10.1042/bsr20182454

Abstract

Long non-coding RNAs (lncRNA) CASC2 is a key player in cancer biology. Our new findings showed that both lncRNA CASC2 and IL-17 were up-regulated in plasma of osteoarthritis patients. Plasma levels of lncRNA CASC2 and IL-17 were significantly and positive correlated only in osteoarthritis patients. Overexpression of lncRNA CASC2 led to up-regulated expression of IL-17 in cells of human chondrocyte cell line CHON-001 (ATCC® CRL-2846™). In addition, overexpression of lncRNA CASC2 inhibited the proliferation, and promoted the apoptosis of chondrocyte. Therefore, lncRNA CASC2 is up-regulated in osteoarthritis and participates in the regulation of IL-17 expression and chondrocyte proliferation and apoptosis.

Highlights

Osteoarthritis is the most frequently diagnosed chronic joint disease that involves both inflammatory processes and other pathological changes [1], which is different from rheumatoid arthritis, an inflammatory disease [2]
In the present study we found that Long non-coding RNAs (lncRNA) CASC2 was up-regulated in osteoarthritis and participated in the regulation of IL-17 expression and chondrocyte proliferation and apoptosis
Results showed that plasma levels of lncRNA CASC2 and IL-17 were significantly and positive correlated in osteoarthritis patients (Figure 2A)

Summary

Introduction

Osteoarthritis is the most frequently diagnosed chronic joint disease that involves both inflammatory processes and other pathological changes [1], which is different from rheumatoid arthritis, an inflammatory disease [2]. It is generally believed that more than 10% of the population will develop osteoarthritis during their life time [3], leading to a heavy burden on public health. Osteoarthritis causes pain or even disability in some severe cases. Osteoarthritis is essentially an inflammatory disease [8]. During the development and progression of osteoarthritis, the altered balance between pro-inflammatory and anti-inflammatory cytokines leads to severe inflammatory response in the body of patients [9]. It has been reported that the level of IL-17, which is a pro-inflammatory factor, determines the severity of osteoarthritis [10]. In rheumatoid arthritis, IL-17 is an inflammation inducers and contributes to synovium matrix destruction [11]

Methods

Results

Conclusion